Biotheus Inc.

BioNTech plans to advance BNT327 to Phase III for triple-negative breast cancer after promising Phase II survival data. BNT327, a PD-L1 x VEGF bispecific, showed 13.5 months of progression-free survival when combined with nab-paclitaxel as first-line therapy for locally advanced or metastatic TNBC.

BioNTech reports Q3 2024 revenues of €1.2 billion, net profit of €198.1 million, and diluted earnings per share of €0.81. The company launched variant-adapted COVID-19 vaccines and initiated Phase 2 trials for BNT327/PM8002 in small-cell lung cancer and triple-negative breast cancer. A Phase 2 trial for mRNA-based individualized cancer vaccine candidate autogene cevumeran is on track for high-risk muscle-invasive urothelial cancer. BioNTech ended Q3 with €17.8 billion in cash and cash equivalents plus security investments, expecting to be at the low end of its full-year 2024 revenue guidance range of €2.5-3.1 billion.